Immunocytochemical detection of hENT1 and hCNT1 in normal tissues, lung cancer cell lines, and NSCLC patient samples

Nucleosides, Nucleotides and Nucleic Acids

Volumn 27, Issue 6-7, 2008, Pages 787-793

  Hubeek, I ^a   Giovannetti, E ^a   Broekhuizen, A J F ^a   Pastor Anglada, M ^b   Kaspers, G J L ^a   Peters, G J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Antimetabolite cytotoxic drugs; Deoxynucleoside analogs; Human concentrative nucleoside transporters (hCNTs); Human equilibrative nucleoside transporters (hENTs); Immunocytochemical staining

Indexed keywords

CONCENTRATIVE NUCLEOSIDE TRANSPORTER; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER; NUCLEOSIDE TRANSPORTER;

CANCER CELL CULTURE; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG NON SMALL CELL CANCER; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CATTLE; CELL LINE, TUMOR; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GENE EXPRESSION REGULATION; HUMANS; LUNG NEOPLASMS; MEMBRANE TRANSPORT PROTEINS; PYRIMIDINES; RNA, MESSENGER; SUBSTRATE SPECIFICITY;

EID: 46749084205     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257770802145942     Document Type: Conference Paper

References (13)

1. Peters, G.J.; van der Wilt, C.L.; Van Moorsel. C.J.; Kroep, J.R.; Bergman, A.M.; Ackland, S.P. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol. Ther. 2000, 87, 227-253.
2. Pastor-Anglada, M.; Cano-Soldado, P.; Molina-Arcas, M.; Lostao, M.P.; Larráyoz, I.; Martínez-Picado, J.; Casado, F.J. Cell entry and export of nucleoside analogues. Virus Res. 2005, 107, 151-164.
3. Clarke, M.L.; Mackey, J.R.; Baldwin, S.A.; Young, J.D.; Cass, C.E. The role of membrane transporters in cellular resistance to anticancer nucleoside drugs. Cancer Treat. Res. 2002, 112, 27-47.
4. Sundaram, M.; Yao, S.Y.; Ingram, J.C.; Berry, Z.A.; Abidi, F.; Cass, C.E.; Baldwin, S.A.; Young, J.D. Topology of a human equilibrative, nitrobenzylthioinosine (NBMPR)-sensitive nucleoside transporter (hENT1) implicated in the cellular uptake of adenosine and anti-cancer drugs. J. Biol. Chem. 2001, 276, 45270-45275.
5. Sigmond, J.; Kamphuis, J.A.; Laan, A.C.; Hoebe, E.K.; Bergman, A.M.; Peters, G.J. The synergistic interaction of gemcitabine and cytosine arabinoside with the ribonucleotide reductase inhibitor triapine is schedule dependent. Biochem. Pharmacol. 2007, 73, 1548-1557.
6. Pastor-Anglada, M.; Casado, F.J. Nucleoside transport into cells: Role of nucleoside transporters SLC28 and SLC29 in cancer chemotherapy. G.J. Peters, ed. In: Deoxynucleoside Analogs in Cancer Therapy. Humana Press, Totowa, NJ, 2006, pp.1-28.
7. Giovannetti, E.; Del, T.M.; Mey, V.; Funel, N.; Nannizzi, S.; Ricci, S.; Orlandini, C.; Boggi, U.; Campani, D.; Del Chiaro, M.; Iannopollo, M; Bevilacqua, G.; Mosca, F.; Danesi, R. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 2006, 66, 3928-3935.
8. Hubeek, I.; Stam, R.W.; Peters, G.J.; Broekhuizen, R.; Meijerink, J.P.; van Wering, E.R.; Gibson, B.E.; Creutzig, U.; Zwaan, C.M.; Cloos, J.; Kuik, D.J.; Pieters, R.; Kaspers, G.J. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia.Br. J. Cancer 2005, 93, 1388-1394.
9. Galmarini, C.M.; Thomas, X.; Calvo, F.; Rousselot, P.; Rabilloud, M.; El Jaffari, A.; Cros, E.; Dumontet, C. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br. J. Haematol. 2002, 117, 860-868.
10. Galmarini, C.M.; Thomas, X.; Calvo, F.; Rousselot, P.; El Jafaari, A.; Cros, E.; Dumontet, C. Potential mechanisms of resistance to cytarabine in AML patients. Leuk. Res. 2002, 26, 621-629.
11. Mori, R.; Ishikawa, T.; Ichikawa, Y.; Taniguchi, K.; Matsuyama, R.; Ueda, M.; Fujii, Y.; Endo, I.; Togo, S.; Danenberg, P.V.; Shimada, H. Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells. Oncol. Rep., 2007, 17, 1201-1205.
12. Achiwa, H.; Oguri, T.; Sato, S.; Maeda, H.; Niimi, T.; Ueda, R. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci. 2004, 95, 753-757.
13. Oguri, T.; Achiwa, H.; Muramatsu, H.; Ozasa, H.; Sato, S.; Shimizu, S.; Yamazaki, H.; Eimoto, T.; Ueda, R. The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer. Cancer Lett. 2007, 256, 112-119.